NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Hospital of China Medical University, Shenyang 110001, China; Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang 110001, China.
NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Hospital of China Medical University, Shenyang 110001, China; Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang 110001, China.
Cytokine. 2023 Jan;161:156056. doi: 10.1016/j.cyto.2022.156056. Epub 2022 Oct 12.
The mortality rate of patients with sepsis has been increasing in recent years. Alterations of biomarkers levels during treatment are important in evaluating treatment efficacy and predicting outcomes in sepsis. This meta-analysis investigated the relationship between changes in cytokine levels after treatment compared with those on hospital admission, and their relationship with the prognosis of patients with sepsis.
From conception until August 4, 2021, a complete literature search of the PubMed, Web of Science, and Cochrane Library electronic databases was done. Observational studies where the outcomes of sepsis patients were divided into non-survivors and survivors and which reported cytokine levels at least before treatment in ICU were included in the current study. Standardized mean difference (SMD) with 95% confidence intervals (CI) values from individual studies were pooled using a random-effects model. Quality assessment, subgroup analysis, publication bias, and sensitivity analyses were all carried out.
A total of 2570 patients with sepsis from 25 eligible studies were included, and 14 of them measured the cytokine levels before and after treatment in ICU. Among IL-6, TNF-α, IL-1β and IL-10 levels, those of IL-6 were significantly lower after treatment in ICU than at baseline in patients with sepsis in the survival group (SMD = -0.69, P < 0.0001), but were comparable in the non-survival group (SMD = -0.99, P = 0.0575). Similarly, post-treatment TNF-α levels were significantly lower than those at baseline only in patients with sepsis in the survival group (SMD = -0.44, P < 0.0001), but not in the non-survival group (SMD =-0.17, P = 0.0842).
This meta-analysis shows that reduced IL-6 and TNF-α levels after sepsis treatment in ICU may be indicators of better prognosis and survival of patients with sepsis.
近年来,脓毒症患者的死亡率一直在上升。治疗过程中生物标志物水平的变化对于评估治疗效果和预测脓毒症患者的预后非常重要。本荟萃分析旨在探讨治疗后与入院时相比细胞因子水平的变化与脓毒症患者预后之间的关系。
从构思到 2021 年 8 月 4 日,我们对 PubMed、Web of Science 和 Cochrane Library 电子数据库进行了全面的文献检索。纳入了将脓毒症患者的结局分为存活者和非存活者,并报告了 ICU 治疗前至少有细胞因子水平的观察性研究。使用随机效应模型对来自单个研究的标准化均数差(SMD)及其 95%置信区间(CI)值进行汇总。进行了质量评估、亚组分析、发表偏倚和敏感性分析。
共有 2570 名脓毒症患者纳入 25 项符合条件的研究,其中 14 项研究在 ICU 中测量了治疗前后的细胞因子水平。在白细胞介素 6(IL-6)、肿瘤坏死因子-α(TNF-α)、白细胞介素 1β(IL-1β)和白细胞介素 10(IL-10)水平中,存活组患者 ICU 治疗后 IL-6 水平明显低于基线水平(SMD=-0.69,P<0.0001),但在非存活组患者中则无差异(SMD=-0.99,P=0.0575)。同样,治疗后 TNF-α水平仅在存活组患者中明显低于基线水平(SMD=-0.44,P<0.0001),而非存活组患者中则无差异(SMD=-0.17,P=0.0842)。
本荟萃分析表明,脓毒症患者 ICU 治疗后 IL-6 和 TNF-α水平降低可能是预后和存活的指标。